Yet another CAR-T cell-therapy company that delivered promising data but couldn't make the financials sustainably work. Quote from the CEO Bryan Kobel, "While

Yet another CAR-T cell-therapy company that delivered promising data but couldn't make the financials sustainably work. Quote from the CEO Bryan Kobel, "While the data shows great promise in Minimal Residual Disease (MRD) as well as potential as a combination therapeutic, the capital market headwinds in cell therapy proved too much to overcome regardless of the success driven by the team. The team showed their mettle throughout the last several years, continuing to push forward, generate strong clinical data, advancing preclinical programs, and countless other achievements and successes that were muted or negated largely by the investment environment in/perception of cell therapy." Burned through $150 million across 8 rounds in 4 years.